Merck Return on Tangible Equity 2012-2026 | MRK
Current and historical return on tangible equity values for Merck (MRK) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Unlock Macrotrends Premium
Start 7-Day Free Trial
Merck Return On Tangible Equity Historical Data
Date
TTM Net Income
Tangible Equity
Return on Tangible Equity
2025-09-30
$19.03B
$11.64B
163.47%
2025-06-30
$16.41B
$9.36B
175.37%
2025-03-31
$17.43B
$7.66B
227.54%
2024-12-31
$17.12B
$5.34B
320.53%
2024-09-30
$12.15B
$2.86B
424.24%
2024-06-30
$13.74B
$1.63B
842.83%
2024-03-31
$2.31B
$-0.28B
-837.02%
2023-12-31
$0.37B
$0.77B
47.62%
2023-09-30
$4.61B
$2.31B
199.83%
2023-06-30
$3.11B
$2.58B
120.79%
2023-03-31
$13.03B
$3.01B
433.32%
2022-12-31
$14.52B
$0.72B
2029.21%
2022-09-30
$15.26B
$-1.92B
-796.55%
2022-06-30
$16.58B
$-1.51B
-1097.58%
2022-03-31
$14.18B
$-1.19B
-1192.35%
2021-12-31
$13.05B
$-2.25B
-579.70%
2021-09-30
$7.20B
$-2.66B
-270.45%
2021-06-30
$5.57B
$-5.48B
-101.67%
2021-03-31
$7.03B
$-7.92B
-88.68%
2020-12-31
$7.07B
$-8.42B
-83.92%
2020-09-30
$11.52B
$-8.43B
-136.61%
2020-06-30
$10.48B
$-7.73B
-135.50%
2020-03-31
$10.15B
$-6.80B
-149.34%
2019-12-31
$9.84B
$-4.78B
-205.97%
2019-09-30
$9.31B
$-3.99B
-233.26%
2019-06-30
$9.36B
$-2.22B
-421.47%
2019-03-31
$8.40B
$-0.54B
-1557.53%
2018-12-31
$6.22B
$0.36B
1728.98%
2018-09-30
$3.35B
$2.00B
166.97%
2018-06-30
$1.34B
$2.70B
49.57%
2018-03-31
$1.58B
$3.61B
43.69%
2017-12-31
$2.39B
$4.31B
55.59%
2017-09-30
$2.85B
$4.99B
57.04%
2017-06-30
$5.09B
$5.03B
101.06%
2017-03-31
$4.35B
$5.06B
85.97%
2016-12-31
$3.92B
$5.03B
77.98%
2016-09-30
$5.49B
$4.93B
111.43%
2016-06-30
$5.13B
$4.68B
109.71%
2016-03-31
$4.61B
$4.39B
105.04%
2015-12-31
$4.44B
$4.23B
105.05%
2015-09-30
$10.78B
$6.97B
154.66%
2015-06-30
$9.85B
$8.87B
111.04%
2015-03-31
$11.17B
$12.30B
90.79%
2014-12-31
$11.92B
$16.26B
73.32%
2014-09-30
$5.39B
$16.46B
32.71%
2014-06-30
$5.61B
$16.73B
33.55%
2014-03-31
$4.52B
$15.15B
29.80%
2013-12-31
$4.40B
$13.99B
31.47%
2013-09-30
$4.53B
$13.50B
33.57%
2013-06-30
$5.14B
$14.21B
36.15%
2013-03-31
$6.02B
$14.79B
40.72%
2012-12-31
$6.17B
$14.01B
44.02%
2012-09-30
$6.76B
$13.07B
51.76%
2012-06-30
$6.72B
$11.52B
58.34%
2012-03-31
$6.95B
$10.17B
68.36%
2011-12-31
$6.26B
$8.81B
71.04%
2011-09-30
$4.22B
$7.43B
56.77%
2011-06-30
$2.87B
$5.70B
50.40%
2011-03-31
$1.60B
$4.12B
38.93%
2010-12-31
$0.86B
$3.06B
28.06%
2010-09-30
$7.84B
$2.24B
349.84%
2010-06-30
$10.92B
$7.43B
147.07%
2010-03-31
$11.73B
$12.07B
97.18%
2009-12-31
$12.85B
$16.43B
78.24%
2009-09-30
$8.03B
$20.81B
38.59%
2009-06-30
$5.70B
$19.36B
29.43%
2009-03-31
$5.91B
$18.74B
31.54%
2008-12-31
$7.79B
$18.10B
43.02%
2008-09-30
$4.53B
$17.31B
26.15%
2008-06-30
$4.96B
$17.54B
28.26%
2008-03-31
$4.87B
$17.29B
28.14%
2007-12-31
$3.27B
$16.98B
19.24%
2007-09-30
$5.38B
$16.77B
32.08%
2007-06-30
$4.80B
$16.53B
29.01%
2007-03-31
$4.62B
$16.61B
27.80%
2006-12-31
$4.43B
$16.89B
26.25%
2006-09-30
$5.08B
$17.19B
29.56%
2006-06-30
$5.56B
$16.83B
33.03%
2006-03-31
$4.78B
$16.38B
29.20%
2005-12-31
$4.63B
$16.04B
28.88%
2005-09-30
$4.63B
$15.83B
29.26%
2005-06-30
$4.54B
$15.67B
28.95%
2005-03-31
$5.58B
$15.52B
35.97%
2004-12-31
$5.83B
$15.13B
38.55%
2004-09-30
$6.11B
$14.65B
41.69%
2004-06-30
$6.64B
$14.13B
47.00%
2004-03-31
$6.74B
$13.35B
50.50%
2003-12-31
$6.83B
$12.55B
54.42%
2003-09-30
$7.33B
$11.88B
61.64%
2003-06-30
$7.35B
$11.09B
66.30%
2003-03-31
$7.24B
$10.45B
69.27%
2002-12-31
$7.15B
$9.90B
72.20%
2002-09-30
$7.12B
$9.30B
76.54%
2002-06-30
$7.19B
$8.69B
82.66%
2002-03-31
$7.25B
$8.23B
88.04%
2001-12-31
$7.28B
$7.87B
92.48%
2001-09-30
$7.18B
$7.60B
94.56%
2001-06-30
$7.07B
$7.17B
98.67%
2001-03-31
$6.98B
$6.57B
106.29%
2000-12-31
$6.82B
$5.84B
116.92%
2000-09-30
$6.63B
$5.39B
123.14%
2000-06-30
$6.34B
$5.17B
122.65%
2000-03-31
$6.09B
$5.18B
117.59%
1999-12-31
$5.89B
$5.31B
111.06%
1999-09-30
$5.72B
$5.02B
113.95%
1999-06-30
$5.55B
$4.77B
116.30%
1999-03-31
$5.38B
$5.21B
103.31%
1998-12-31
$5.25B
$5.53B
94.90%
1998-09-30
$5.09B
$5.86B
86.85%
1998-06-30
$4.92B
$6.31B
77.96%
1998-03-31
$4.76B
$6.02B
79.01%
1997-12-31
$4.61B
$5.85B
78.85%
1997-09-30
$4.42B
$5.70B
77.45%
1997-06-30
$4.22B
$5.36B
78.79%
1997-03-31
$4.04B
$5.04B
80.06%
1996-12-31
$3.88B
$4.83B
80.42%
1996-09-30
$3.70B
$4.75B
77.88%
1996-06-30
$3.56B
$4.73B
75.16%
1996-03-31
$3.44B
$4.67B
73.76%
1995-12-31
$3.34B
$4.44B
75.10%
1995-09-30
$3.25B
$4.20B
77.46%
1995-06-30
$3.17B
$4.52B
70.26%
1995-03-31
$3.08B
$4.78B
64.39%
1994-12-31
$3.00B
$5.04B
59.45%
1994-09-30
$2.90B
$4.90B
59.10%
1994-06-30
$2.82B
$5.03B
56.03%
1994-03-31
$2.23B
$5.09B
43.74%
1993-12-31
$2.17B
$5.30B
40.89%
1993-09-30
$2.10B
$5.86B
35.85%
1993-06-30
$2.04B
$5.80B
35.17%
1993-03-31
$2.51B
$5.87B
42.78%
1992-12-31
$2.48B
$5.84B
42.43%
1992-09-30
$2.40B
$5.66B
42.37%
1992-06-30
$2.30B
$5.44B
42.39%
1992-03-31
$2.22B
$5.18B
42.75%
1991-12-31
$2.12B
$4.91B
43.21%
1991-09-30
$2.03B
$4.64B
43.84%
1991-06-30
$1.95B
$4.40B
44.22%
1991-03-31
$1.86B
$4.22B
44.13%
1990-12-31
$1.78B
$4.06B
43.87%
1990-09-30
$1.71B
$3.98B
42.88%
1990-06-30
$1.63B
$3.88B
42.14%
1990-03-31
$1.56B
$3.75B
41.65%
1989-12-31
$1.50B
$3.65B
41.01%
1989-09-30
$1.44B
$3.48B
41.22%
1989-06-30
$1.36B
$3.32B
40.91%
1989-03-31
$1.28B
$3.16B
40.42%
1988-12-31
$1.21B
$2.97B
40.67%
1988-09-30
$1.13B
$2.92B
38.81%
1988-06-30
$1.06B
$2.96B
35.71%
1988-03-31
$0.98B
$3.04B
32.08%
1987-12-31
$0.91B
$3.12B
29.00%
Sector
Industry
Market Cap
Revenue
Medical Large Cap Pharmaceutical $299.893B
$65.011B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
